Atul Dandekar is CSBO at Maze Therapeutics, Inc. (MAZE). They have made 3 open-market trades across 1 company since 2025, most recently 2026-09-29.
CIK 0002050167
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MAZE | 32,316 | $890K |
Shares reported on the most recent Form 4, priced at the 2026-10-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MAZE | SELL · 10b5-1 | 2026-09-29 | 2026-10-01 | $27.06 | $203K | -0.7% | — | — |
| MAZE | SELL | 2026-09-02 | 2026-09-04 | $26.24 | $169K | -8.5% | +3.2% | — |
| MAZE | SELL · 10b5-1 | 2026-08-28 | 2026-08-31 | $27.58 | $207K | -6.8% | +2.9% | — |
| MAZE | SELL · 10b5-1 | 2026-07-29 | 2026-07-31 | $27.34 | $205K | +5.9% | +2.3% | — |
| MAZE | SELL · 10b5-1 | 2026-06-29 | 2026-07-01 | $28.02 | $210K | -0.4% | -10.4% | -10.0% |
| MAZE | SELL · 10b5-1 | 2026-05-29 | 2026-06-02 | $26.34 | $198K | -0.7% | +29.1% | +9.8% |
| MAZE | SELL · 10b5-1 | 2026-04-29 | 2026-05-01 | $25.37 | $190K | -1.7% | -7.1% | +0.8% |
| MAZE | SELL · 10b5-1 | 2026-03-30 | 2026-04-01 | $29.34 | $220K | -2.1% | -3.8% | +5.4% |
| MAZE | SELL | 2026-02-27 | 2026-03-03 | $45.43 | $341K | +7.8% | -38.4% | -45.4% |
| MAZE | SELL | 2026-01-29 | 2026-02-02 | $44.27 | $332K | +0.5% | -0.7% | -42.4% |
| MAZE | SELL · 10b5-1 | 2025-12-29 | 2025-12-31 | $40.56 | $5.9M | +1.3% | +6.7% | -26.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.